Article
Urology & Nephrology
Yan Li, Hui Shi, Zhenjun Zhao, Minghui Xu
Summary: In this study, alterations in gene expression profiles in rat's epididymis after bilateral castration were identified, as well as castration-dependent and -independent genes and pathways in CRPC using publicly available gene expression profiles. Key genes NUSAP1 and NCAPG were proposed as potential biomarkers for the diagnosis and prognosis of CRPC. This research provides insights into gene regulation in CRPC development and progression.
Article
Multidisciplinary Sciences
Jae Duck Choi, Tae Jin Kim, Byong Chang Jeong, Hwang Gyun Jeon, Seong Soo Jeon, Min Yong Kang, Seon Yong Yeom, Seong Il Seo
Summary: Abnormal expression of ISL1 has been closely associated with cancer development and progression, with particular focus on its role in the androgen receptor-dependent prostate cancer cell growth, EMT, and enzalutamide resistance. ISL1 knockdown was found to inhibit AR activity, cell growth, and EMT in enzalutamide-resistant cells, suggesting its potential as a therapeutic target for CRPC. The study highlights the importance of downregulating ISL1 expression to overcome enzalutamide resistance and improve survival in CRPC patients.
SCIENTIFIC REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Kai Lu, Zheng Li, Qiang Hu, Jianfei Sun, Ming Chen
Summary: In this work, a CRPC-targeting nanocomposite with fine biocompatibility was developed using CRPC cell membranes as biomimetic vectors. The encapsulated chemotherapy drug DTX was successfully delivered to the targeting site, improving therapeutic efficiency. The use of CRPC cell membrane coating enabled homotypic targeting and significantly improved therapeutic efficacy in a mice model bearing CRPC tumors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Rafael S. Martinez, Mark J. Salji, Linda Rushworth, Chara Ntala, Giovanny Rodriguez Blanco, Ann Hedley, William Clark, Paul Peixoto, Eric Hervouet, Elodie Renaude, Sonia H. Y. Kung, Laura C. A. Galbraith, Colin Nixon, Sergio Lilla, Gillian M. Mackay, Ladan Fazli, Luke Gaughan, David Sumpton, Martin E. Gleave, Sara Zanivan, Arnaud Blomme, Hing Y. Leung
Summary: This study identified SLFN5 as a novel regulator of the LAT1 amino acid transporter in castration-resistant prostate cancer (CRPC), contributing to mTORC1 activity. High expression of SLFN5 in CRPC tumors was correlated with poor patient outcome, indicating its clinical relevance as a potential target for CRPC treatment.
Article
Pharmacology & Pharmacy
Sisi Qin, Huanyao Gao, Wootae Kim, Huan Zhang, Yayun Gu, Krishna R. Kalari, Jason P. Sinnwell, Jodi A. Scholz, Fang Xie, Ping Yin, Jia Yu, Bo Qin, Yongxian Zhuang, Lixuan Wei, Winston Tan, Alan H. Bryce, Richard M. Weinshilboum, Liewei Wang
Summary: This study identified three drugs that could potentially be alternative treatments for abiraterone nonresponders in patients with metastatic castration-resistant prostate cancer. Additionally, eleven genes targeted by these drugs were associated with worse outcomes in both PROMOTE and Stand Up To Cancer cohorts. Further clinical investigation is needed to determine the efficacy of these alternative therapies.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Biochemistry & Molecular Biology
David Ka-Wai Leung, Peter Ka-Fung Chiu, Chi-Fai Ng, Jeremy Yuen-Chun Teoh
Summary: The management of castration-resistant prostate cancer has seen significant progress, with three novel hormonal agents showing survival benefits in non-metastatic patients and a wider range of management options being investigated for metastatic disease.
Article
Biochemistry & Molecular Biology
Sarina Cameron, Genevieve Deblois, James R. Hawley, Aditi Qamra, Stanley Zhou, Seyed Ali Madani Tonekaboni, Alexander Murison, Romy Van Vliet, Juan Liu, Jason W. Locasale, Mathieu Lupien
Summary: Predicting and treating recurrence in intermediate-risk prostate cancer patients is challenging. This study found that chronic hypoxia leads to an androgen-independent state in prostate cancer cells, promoting cancer progression. These findings may provide additional strategies for treating hypoxic prostate cancer.
Article
Medicine, General & Internal
Oliver Sartor, Johann de Bono, Kim N. Chi, Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Luke T. Nordquist, Nitin Vaishampayan, Ghassan El-Haddad, Chandler H. Park, Tomasz M. Beer, Alison Armour, Wendy J. Perez-Contreras, Michelle DeSilvio, Euloge Kpamegan, Germo Gericke, Richard A. Messmann, Michael J. Morris, Bernd J. Krause
Summary: The radioligand therapy with Lu-177-PSMA-617 prolonged both imaging-based progression-free survival and overall survival in patients with PSMA-positive metastatic castration-resistant prostate cancer when added to standard care. Adverse events were more common with Lu-177-PSMA-617 but did not significantly impact quality of life.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Michele Iuliani, Sonia Simonetti, Giulia Ribelli, Silvia Cavaliere, Bruno Vincenzi, Giuseppe Tonini, Francesco Pantano, Daniele Santini
Summary: Abiraterone, a selective inhibitor of androgen biosynthesis, has been approved for the treatment of prostate cancer. This study provides evidence that abiraterone can inhibit prostate cancer cell proliferation through modulation of multiple osteoblast proliferative signals.
Article
Oncology
Eric Feng, Nicholas R. Rydzewski, Meng Zhang, Arian Lundberg, Matthew Bootsma, Kyle T. Helzer, Joshua M. Lang, Rahul Aggarwal, Eric J. Small, David A. Quigley, Martin Sjostrom, Shuang G. Zhao
Summary: In this study, the researchers identified the intrinsic molecular subtypes of metastatic castration-resistant prostate cancer (mCRPC) and assessed their molecular and clinical correlates using a large cohort with gene expression data. The results showed the heterogeneity of mCRPC beyond currently accepted molecular phenotypes, emphasizing the need for transcriptome-wide profiling in future studies to understand the impact of these differences on treatment responses and outcomes.
CLINICAL CANCER RESEARCH
(2022)
Review
Biochemistry & Molecular Biology
Yasemin Sanli, Duygu Has Simsek, Oner Sanli, Rathan M. Subramaniam, Ayse Tuba Kendi
Summary: Lu-177-PSMA therapy shows promising clinical efficacy in patients with mCRPC, with predictors of efficacy being significant. Ongoing clinical trials, including a phase III multicenter FDA registration trial, are currently being conducted in the United States.
Article
Oncology
Moloud A. Sooreshjani, Kumar Nikhil, Mohini Kamra, Dung N. Nguyen, Dinesh Kumar, Kavita Shah
Summary: Prostate cancer is the leading cause of cancer-related death in men, with most patients progressing to castration-resistant prostate cancer (CRPC) which currently has no cure. The study identified LIMK2 as a key player in CRPC and its negative regulation of NKX3.1, a prostate-specific tumor suppressor. Inhibiting LIMK2 to rescue NKX3.1 loss presents a promising therapeutic strategy for preventing and delaying prostate cancer progression, by co-targeting driver pathways such as AR, ARv7, and AKT signaling.
Article
Oncology
Jun Li, Nan Liu, Hong Zhou, Peng Xian, Yanping Song, Xianli Tang, Yuan Li, Michael Basler
Summary: This study found that immunoproteasome inhibition has a significant effect on suppressing the progression of castration-resistant prostate cancer (CRPC). The results showed that immunoproteasome inhibition prevents CRPC progression by suppressing inflammation and inducing apoptosis of CRPC cells through activating the unfolded protein response.
BRITISH JOURNAL OF CANCER
(2023)
Editorial Material
Oncology
Haider Al-Janabi, Claire E. Lewis
Summary: Androgen deprivation therapy (ADT) is a frontline treatment for early and metastatic prostate cancer, but tumor resistance to ADT can lead to major clinical consequences. Tumor-associated macrophages have been shown to drive tumor resistance to various anticancer therapies, and researchers have now identified a novel mechanism involving the transfer of cholesterol from macrophages to cancer cells during ADT, which activates androgen receptors and promotes tumor resistance.
Article
Biochemistry & Molecular Biology
Chaima Cherif, Dang Tan Nguyen, Clement Paris, Thi Khanh Le, Thibaud Sefiane, Nadine Carbuccia, Pascal Finetti, Max Chaffanet, Abdessamad El Kaoutari, Julien Vernerey, Ladan Fazli, Martin Gleave, Mohamed Manai, Philippe Barthelemy, Daniel Birnbaum, Francois Bertucci, David Taieb, Palma Rocchi
Summary: Menin (MEN1) protein is highly regulated by HSP27, overexpressed in high-grade PC and CRPC, and high MEN1 mRNA expression is associated with decreased biochemical relapse-free and overall survival. Silencing Menin helps inhibit CRPC cell proliferation, tumor growth, and restore chemotherapeutic sensitivity.